Search

Displaying results 7341 - 7350 of 8412 in total
  1. Drug

    Flizasertib

    go.drugbank.com/drugs/DB21613
    Investigational

    Flizasertib has a monoisotopic molecular weight of 271.11 Da.

  2. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

  3. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.

  4. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.

  5. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.

  6. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.

  7. Drug

    FB-825

    go.drugbank.com/drugs/DB17598
    Investigational

    FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells.

  8. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia

  9. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

  10. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates